The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...

Our top 5 highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) include articles and interviews introducing ...

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...